![]() |
市场调查报告书
商品编码
1833581
2032 年手持式超音波市场预测:按感测器类型、软体和连接性、资料管理功能、技术、应用、最终用户和地区进行的全球分析Handheld Ultrasound Market Forecasts to 2032 - Global Analysis By Transducer Type, Software & Connectivity, Data Management Features, Technology, Application, End User and By Geography |
根据 Stratistics MRC 的数据,全球掌上超音波市场预计在 2025 年达到 4.02 亿美元,到 2032 年将达到 10.3722 亿美元,预测期内的复合年增长率为 14.5%。
掌上超音波是一种小型可携式成像工具,旨在利用声波捕捉器官、组织和血液循环的即时影像。与传统超音波系统不同,它结构紧凑、操作灵活,方便床边检查和现场使用。它能够快速提供诊断讯息,并支持医护人员进行即时临床评估。其多功能性使其成为急诊医学、加护治疗和第一线医疗领域的宝贵工具,提高了重要诊断影像的可近性。
根据世界卫生组织(WHO)发布的数据,预计2022年全球将新增2,000万名癌症病例。
慢性病增多
心血管疾病、糖尿病和癌症等慢性疾病的增多,推动了对携带式诊断解决方案的需求。手持式超音波设备越来越多地用于照护现场影像,以支持早期发现和持续监测。随着全球人口老化,医疗保健系统正在转向主动、个人化的照护模式。这种紧凑的影像工具使临床医生能够在床边进行评估,从而减少了昂贵且耗时的转诊需求。探头小型化和人工智慧辅助影像解读的技术进步正在提高诊断准确性。医疗保健的去中心化趋势正在加速手持式超音波在医院、诊所和家庭中的普及。
有限的影像品质和高级功能
有限的处理能力和换能器功能限制了它们在复杂诊断场景中的应用。许多手持式型号尚未开发弹性成像、多普勒成像和三维重建等高级功能。这些限制可能会阻碍临床决策,尤其是在急诊室和手术室等高风险环境中。製造商面临着在紧凑设计与高性能影像处理之间取得平衡的挑战。这可能会减缓其在需要精确和全面可视化的专科领域的应用。
与远端医疗和远端患者监护的整合
掌上超音波与远端医疗平台的融合开闢了远距离诊断的新领域。医生现在可以即时预约扫描并远端解读影像,从而改善医疗资源匮乏地区的就诊体验。与云端基础系统的整合实现了无缝资料共用和纵向患者追踪。新兴趋势包括人工智慧驱动的影像分析和可连接智慧型手机的探头,这些技术提高了非专业人士的易用性。这些创新在家庭医疗保健、乡村诊所和灾难应变场景中尤其有用。随着虚拟护理成为主流,掌上超音波有望成为远端患者监护生态系统的基石。
资料安全和隐私问题
超音波影像的数位化引发了人们对患者资料保护的担忧。无线传输和云端储存使敏感的医疗资讯面临潜在的洩漏风险。要遵守《健康保险流通与责任法案》(HIPAA) 和《一般资料保护规范》(GDPR) 等法规,需要强大的加密和安全的存取通讯协定。小型製造商可能难以实施企业级网路安全措施,从而增加了其漏洞。人工智慧和物联网的整合进一步加剧了资料管治的复杂性,尤其是在涉及第三方平台时。如果没有严格的保障措施,人们对掌上超音波技术的信任可能会被削弱,从而推迟其在临床工作流程中的应用。
新冠疫情加速了掌上超音波在快速床边评估中的应用,尤其是在呼吸和心臟评估方面。医院优先考虑携带式成像,以最大程度地减少患者出行并降低交叉污染的风险。虽然供应链中断最初阻碍了设备的供应,但随着临床医生寻求灵活的诊断工具,需求激增。监管机构迅速核准并授予紧急使用授权,为第一线医疗服务提供支援。这场危机也刺激了技术创新,例如无线探头和非放射科医生的人工智慧引导扫描。疫情过后,掌上超音波越来越被视为提供弹性和扩充性医疗服务的重要工具。
预计线性阵列部分将是预测期内最大的
线性阵列探头因其在血管、肌肉骨骼和浅层器官成像方面的多功能性,预计将在预测期内占据最大的市场份额。这些探头在急诊和门诊护理中已成为必不可少的,因为它们能够提供高解析度成像,用于表面诊断。波束成形和讯号处理技术的进步提高了清晰度和诊断可靠性。与行动平台的整合实现了即时影像共用和註释。该细分市场受益于运动医学、麻醉学和创伤护理领域日益增长的需求。随着临床应用的不断扩展,线性阵列探头在产量和技术创新方面继续保持领先地位。
预计家庭医疗保健领域在预测期内将实现最高复合年增长率
预计家庭医疗保健领域将在预测期内呈现最高成长率。患者和看护者越来越有能力在远端监督下进行基本扫描。紧凑易用且配备人工智慧引导的设备使超音波在临床环境之外也普及。慢性病管理和人口老化正在推动家庭诊断的需求。穿戴式感测器与远端医疗平台的整合正在增强护理的连续性。随着报销模式不断发展以支援远距服务,居家超音波正成为个人化医疗的关键推动力。
预计亚太地区将在预测期内占据最大的市场份额,这得益于医疗基础设施的不断扩张和诊断需求的不断增长。中国、印度和日本等国家正在投资可携式成像技术,以弥合都市区医疗差距。政府推动数位医疗和本地製造的措施正在推动这些设备的普及。人工智慧超音波探头和智慧型手机整合探头在该地区迅速普及。全球原始设备製造商 (OEM) 与本地新兴企业之间的策略合作伙伴关係正在加速技术创新并降低价格。在中阶不断壮大和医疗保健意识不断增强的推动下,亚太地区将继续成为手持式超音波的成长动力。
得益于其技术领先地位和强劲的研发投入,北美预计将在预测期内呈现最高的复合年增长率。美国和加拿大正在率先推出具有人工智慧诊断和云端连接功能的智慧超音波系统。医院正在将手持设备与电子健康记录和远端护理平台结合。监管机构正在简化下一代诊断影像工具的核准,以鼓励其加速商业化进程。该地区受益于强有力的报销政策和照护现场技术的广泛采用。随着精准诊断的发展势头强劲,北美将继续引领手持超音波创新的标竿。
According to Stratistics MRC, the Global Handheld Ultrasound Market is accounted for $402.00 million in 2025 and is expected to reach $1037.22 million by 2032 growing at a CAGR of 14.5% during the forecast period. A handheld ultrasound is a small, portable imaging tool designed to capture live visuals of organs, tissues, and circulation using sound waves. Unlike conventional ultrasound systems, it is compact, highly mobile, and convenient for use in bedside examinations or field conditions. Offering rapid diagnostic insights, it supports healthcare providers in immediate clinical assessments. Its versatility makes it valuable in emergency medicine, intensive care, and frontline healthcare, improving accessibility to essential diagnostic imaging.
According to data published by the World Health Organization (WHO), there were an estimated 20.0 million new cancer cases globally in 2022.
Rising prevalence of chronic diseases
The growing burden of chronic illnesses such as cardiovascular disease, diabetes, and cancer is fueling demand for portable diagnostic solutions. Handheld ultrasound devices are increasingly used for point-of-care imaging to support early detection and ongoing monitoring. As global populations age, healthcare systems are shifting toward proactive and personalized care models. These compact imaging tools enable clinicians to perform bedside assessments, reducing the need for costly and time-consuming referrals. Technological advancements in probe miniaturization and AI-powered image interpretation are enhancing diagnostic accuracy. The trend toward decentralized healthcare is accelerating the adoption of handheld ultrasound across hospitals, clinics, and home settings.
Limited image quality and advanced features
Limitations in processing power and transducer capabilities restrict their use in complex diagnostic scenarios. Advanced features like elastography, Doppler imaging, and 3D reconstruction are still underdeveloped in many handheld models. These constraints can hinder clinical decision-making, especially in high-stakes environments like emergency rooms or surgical suites. Manufacturers face challenges in balancing compact design with high-performance imaging. As a result, adoption may be slower in specialties that demand precision and comprehensive visualization.
Integration with telemedicine and remote patient monitoring
The convergence of handheld ultrasound with telehealth platforms is opening new frontiers in remote diagnostics. Physicians can now guide scans in real-time and interpret images from afar, improving access in underserved regions. Integration with cloud-based systems allows seamless data sharing and longitudinal patient tracking. Emerging trends include AI-assisted image analysis and smartphone-connected probes that enhance usability for non-specialists. These innovations are particularly valuable in home healthcare, rural clinics, and disaster response scenarios. As virtual care becomes mainstream, handheld ultrasound is poised to become a cornerstone of remote patient monitoring ecosystems.
Data security and privacy concerns
The digitization of ultrasound imaging raises significant concerns around patient data protection. Wireless transmission and cloud storage expose sensitive health information to potential breaches. Compliance with regulations such as HIPAA and GDPR requires robust encryption and secure access protocols. Smaller manufacturers may struggle to implement enterprise-grade cybersecurity measures, increasing vulnerability. The integration of AI and IoT further complicates data governance, especially when third-party platforms are involved. Without stringent safeguards, trust in handheld ultrasound technology could be undermined, slowing its adoption in clinical workflows.
The COVID-19 pandemic accelerated the use of handheld ultrasound for rapid bedside assessments, especially in respiratory and cardiac evaluations. Hospitals prioritized portable imaging to minimize patient movement and reduce cross-contamination risks. Supply chain disruptions initially hampered device availability, but demand surged as clinicians sought flexible diagnostic tools. Regulatory bodies responded with expedited approvals and emergency use authorizations to support frontline care. The crisis also catalyzed innovation in wireless probes and AI-guided scanning for non-radiologists. Post-pandemic, handheld ultrasound is increasingly viewed as an essential tool for resilient and scalable healthcare delivery.
The linear arraysegment is expected to be the largest during the forecast period
The linear array segment is expected to account for the largest market share during the forecast period, due to its versatility in vascular, musculoskeletal, and superficial organ imaging. These probes offer high-resolution imaging for surface-level diagnostics, making them indispensable in emergency and outpatient settings. Advancements in beamforming and signal processing are improving clarity and diagnostic confidence. Integration with mobile platforms enables real-time sharing and annotation of images. The segment benefits from rising demand in sports medicine, anesthesiology, and trauma care. As clinical applications expand, linear array probes continue to lead in both volume and innovation.
The home healthcare segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate, driven by the shift toward decentralized care. Patients and caregivers are increasingly empowered to perform basic scans under remote supervision. Compact, user-friendly devices with AI guidance are making ultrasound accessible beyond clinical environments. The rise of chronic disease management and aging populations is fueling demand for in-home diagnostics. Integration with wearable sensors and telehealth platforms is enhancing continuity of care. As reimbursement models evolve to support remote services, home-based ultrasound is becoming a key enabler of personalized medicine.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising diagnostic demand. Countries like China, India, and Japan are investing in portable imaging to bridge gaps in rural and urban care. Government initiatives promoting digital health and local manufacturing are boosting device penetration. The region is witnessing rapid adoption of AI-enabled ultrasound and smartphone-integrated probes. Strategic collaborations between global OEMs and regional startups are accelerating innovation and affordability. With a growing middle class and increasing healthcare awareness, Asia Pacific remains a powerhouse for handheld ultrasound growth.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by technological leadership and robust R&D investment. The U.S. and Canada are pioneering smart ultrasound systems with AI diagnostics and cloud connectivity. Hospitals are integrating handheld devices into electronic health records and remote care platforms. Regulatory agencies are streamlining approvals for next-gen imaging tools, encouraging rapid commercialization. The region benefits from strong reimbursement policies and high adoption of point-of-care technologies. As precision diagnostics gain momentum, North America continues to set the benchmark for handheld ultrasound innovation.
Key players in the market
Some of the key players in Handheld Ultrasound Market include GE HealthCare Technologies Inc., Healcerion Co., Ltd., Siemens Healthineers AG, EchoNous Inc., Koninklijke Philips N.V., Aco Healthcare Co., Ltd., Canon Medical Systems Corporation, DGH Technology, Inc., FUJIFILM Holdings Corporation, Dawei Group, Mindray Medical International Ltd., BMV AG, Butterfly Network Inc., CHISON Medical Technologies Co., Ltd., and Clarius Mobile Health Corp.
In September2025, GE HealthCare announced it has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer's disease to meet the growing demand for MRI in personalized treatment planning.
In September2025, FUJIFILM Biotechnologies announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.